In agreement with expectations expressed in the comment letter by Heyman et al. (1), most of the patients (72%) included in the Diabetes and Lifestyle Cohort Twente used agents that exert renin angiotensin aldosterone system (RAAS) blockade (2). None of the included patients used an inhibitor of sodium–glucose cotransporter 2 (SGLT2). Of note, medication use was assessed at baseline, and there is no information regarding either initiation of an SGLT2 inhibitor or changes in usage and/or dosage of RAAS blockade during follow-up.
Patiëntvoorbeelden m.b.t. vergoeding
- ten laste van verzekeraar
- geen vergoeding door verzekeraar